Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro
Copyright © 2024. Published by Elsevier B.V..
BACKGROUND: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has lasted for three years. Coinfection with seasonal influenza may occur resulting in more severe diseases. The interaction between these two viruses for infection and the effect of antiviral treatment remains unclear.
METHODS: A SARS-CoV-2 and influenza H1N1 coinfection model on Calu-3 cell line was established, upon which the simultaneous and sequential coinfection was evaluated by comparing the viral load. The efficacy of molnupiravir and baloxavir against individual virus and coinfection were also studied.
RESULTS: The replication of SARS-CoV-2 was significantly interfered when the influenza virus was infected simultaneously or in advance (p < 0.05). On the contrary, the replication of the influenza virus was not affected by the SARS-CoV-2. Molnupiravir monotherapy had significant inhibitory effect on SARS-CoV-2 when the concentration reached to 6.25 μM but did not show any significant anti-influenza activity. Baloxavir was effective against influenza within the dosage range and showed significant effect of anti-SARS-CoV-2 at 16 μM. In the treatment of coinfection, molnupiravir had significant effect for SARS-CoV-2 from 6.25 μM to 100 μM and inhibited H1N1 at 100 μM (p < 0.05). The tested dosage range of baloxavir can inhibit H1N1 significantly (p < 0.05), while at the highest concentration of baloxavir did not further inhibit SARS-CoV-2, and the replication of SARS-CoV-2 significantly increased in lower concentrations. Combination treatment can effectively inhibit influenza H1N1 and SARS-CoV-2 replication during coinfection. Compared with molnupiravir or baloxavir monotherapy, combination therapy was more effective in less dosage to inhibit the replication of both viruses.
CONCLUSIONS: In coinfection, the replication of SARS-CoV-2 would be interfered by influenza H1N1. Compared with molnupiravir or baloxavir monotherapy, treatment with a combination of molnupiravir and baloxavir should be considered for early treatment in patients with SARS-CoV-2 and influenza coinfection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:345 |
|---|---|
| Enthalten in: |
Virus research - 345(2024) vom: 18. Apr., Seite 199371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Danlei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral |
|---|
| Anmerkungen: |
Date Revised 28.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.virusres.2024.199371 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371107202 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371107202 | ||
| 003 | DE-627 | ||
| 005 | 20240428232038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.virusres.2024.199371 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1391.xml |
| 035 | |a (DE-627)NLM371107202 | ||
| 035 | |a (NLM)38621598 | ||
| 035 | |a (PII)S0168-1702(24)00064-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Danlei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has lasted for three years. Coinfection with seasonal influenza may occur resulting in more severe diseases. The interaction between these two viruses for infection and the effect of antiviral treatment remains unclear | ||
| 520 | |a METHODS: A SARS-CoV-2 and influenza H1N1 coinfection model on Calu-3 cell line was established, upon which the simultaneous and sequential coinfection was evaluated by comparing the viral load. The efficacy of molnupiravir and baloxavir against individual virus and coinfection were also studied | ||
| 520 | |a RESULTS: The replication of SARS-CoV-2 was significantly interfered when the influenza virus was infected simultaneously or in advance (p < 0.05). On the contrary, the replication of the influenza virus was not affected by the SARS-CoV-2. Molnupiravir monotherapy had significant inhibitory effect on SARS-CoV-2 when the concentration reached to 6.25 μM but did not show any significant anti-influenza activity. Baloxavir was effective against influenza within the dosage range and showed significant effect of anti-SARS-CoV-2 at 16 μM. In the treatment of coinfection, molnupiravir had significant effect for SARS-CoV-2 from 6.25 μM to 100 μM and inhibited H1N1 at 100 μM (p < 0.05). The tested dosage range of baloxavir can inhibit H1N1 significantly (p < 0.05), while at the highest concentration of baloxavir did not further inhibit SARS-CoV-2, and the replication of SARS-CoV-2 significantly increased in lower concentrations. Combination treatment can effectively inhibit influenza H1N1 and SARS-CoV-2 replication during coinfection. Compared with molnupiravir or baloxavir monotherapy, combination therapy was more effective in less dosage to inhibit the replication of both viruses | ||
| 520 | |a CONCLUSIONS: In coinfection, the replication of SARS-CoV-2 would be interfered by influenza H1N1. Compared with molnupiravir or baloxavir monotherapy, treatment with a combination of molnupiravir and baloxavir should be considered for early treatment in patients with SARS-CoV-2 and influenza coinfection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a Baloxavir | |
| 650 | 4 | |a Coinfection | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Molnupiravir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Leung, Ka-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Hoi-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ruiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yujing |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiaochun |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Kwok-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Ivan Fan-Ngai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virus research |d 1984 |g 345(2024) vom: 18. Apr., Seite 199371 |w (DE-627)NLM01292136X |x 1872-7492 |7 nnns |
| 773 | 1 | 8 | |g volume:345 |g year:2024 |g day:18 |g month:04 |g pages:199371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.virusres.2024.199371 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 345 |j 2024 |b 18 |c 04 |h 199371 | ||